Letrozole
Information
- Drug Name
- Letrozole
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| breast cancer |
ESR1 OVEREXPRESSION ( ENST00000206249.8 ) ESR1 OVEREXPRESSION ( ENST00000206249.8 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 25524798 | Detail |
| Her2-receptor negative breast cancer |
CDKN2A LOSS ( ENST00000579755.2 ) CDKN2A LOSS ( ENST00000579755.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 26715889 | Detail |
| breast cancer |
ESR1 p.Asp538Gly (p.D538G) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) ESR1 p.Asp538Gly (p.D538G) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 27556863 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A phase 2 clinical trial evaluated 165 patients wi... | ESR1 |
ESR1 OVEREXPRESSION ( ENST00000206249.8 ) ESR1 OVEREXPRESSION ( ENST00000206249.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| A patient with metastatic ER-positive, her2-negati... | CDKN2A |
CDKN2A LOSS ( ENST00000579755.2 ) CDKN2A LOSS ( ENST00000579755.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a study of 16 patients with metastatic breast c... | ESR1 |
ESR1 p.Asp538Gly (p.D538G) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) ESR1 p.Asp538Gly (p.D538G) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) |
Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03099174 | Active, not recruiting | Phase 1 | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | May 4, 2017 | May 30, 2024 |
| NCT03772353 | Active, not recruiting | Phase 1/Phase 2 | Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer | May 12, 2019 | December 10, 2025 |
| NCT00382070 | Active, not recruiting | Phase 3 | Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer | August 2006 | April 2025 |
| NCT03056755 | Active, not recruiting | Phase 2 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments | August 14, 2017 | July 17, 2025 |
| NCT03747042 | Active, not recruiting | Phase 2 | Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer | November 27, 2018 | November 30, 2024 |
| NCT04393285 | Active, not recruiting | Phase 2 | Abemaciclib and Letrozole to Treat Endometrial Cancer | October 10, 2020 | December 1, 2025 |
| NCT00412022 | Active, not recruiting | Phase 3 | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | March 2004 | November 2024 |
| NCT03008408 | Active, not recruiting | Phase 2 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | August 18, 2017 | August 31, 2028 |
| NCT03006172 | Active, not recruiting | Phase 1 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | December 13, 2016 | November 30, 2024 |
| NCT02947685 | Active, not recruiting | Phase 3 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | June 21, 2017 | July 31, 2026 |
| NCT03673124 | Active, not recruiting | Phase 2 | Ribociclib and Letrozole Treatment in Ovarian Cancer | December 14, 2018 | December 31, 2024 |
| NCT03671330 | Active, not recruiting | Phase 2 | Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | August 29, 2018 | April 15, 2025 |
| NCT01272037 | Active, not recruiting | Phase 3 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | January 15, 2011 | October 1, 2032 |
| NCT04300790 | Active, not recruiting | Phase 2 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | October 23, 2020 | June 30, 2026 |
| NCT00310180 | Active, not recruiting | Phase 3 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | April 7, 2006 | September 30, 2030 |
| NCT05035836 | Active, not recruiting | Phase 2 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | November 16, 2021 | December 29, 2024 |
| NCT05918718 | Active, not recruiting | Phase 1/Phase 2 | Assessment of the Efficacy of Letrozole in the Treatment of Ectopic Pregnancy | January 20, 2023 | December 20, 2024 |
| NCT04293393 | Active, not recruiting | Phase 2 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | October 2, 2020 | February 28, 2033 |
| NCT02764541 | Active, not recruiting | Phase 2 | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | May 24, 2016 | April 2031 |
| NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
| NCT04176354 | Active, not recruiting | Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy | January 25, 2019 | December 1, 2022 | |
| NCT02763566 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | December 5, 2016 | December 31, 2024 |
| NCT02712723 | Active, not recruiting | Phase 2 | Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer | February 2016 | April 2023 |
| NCT04059484 | Active, not recruiting | Phase 2 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | October 22, 2019 | September 30, 2024 |
| NCT03633331 | Active, not recruiting | Phase 2 | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | August 15, 2018 | August 2024 |
| NCT02661932 | Active, not recruiting | Phase 4 | Fertility Preservation in Breast Cancer Patients | November 2012 | September 2023 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT03283384 | Active, not recruiting | Phase 2 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. | June 15, 2019 | August 2027 |
| NCT02297438 | Active, not recruiting | Phase 3 | A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] | March 23, 2015 | December 31, 2024 |
| NCT04002141 | Active, not recruiting | Phase 2 | Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis | September 17, 2019 | July 1, 2024 |
| NCT03962647 | Active, not recruiting | Early Phase 1 | A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer | July 8, 2019 | May 2025 |
| NCT01674140 | Active, not recruiting | Phase 3 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | September 12, 2013 | January 2030 |
| NCT03219476 | Active, not recruiting | Phase 2 | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | February 5, 2017 | July 1, 2024 |
| NCT04603183 | Active, not recruiting | Phase 2 | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | June 2, 2021 | June 30, 2025 |
| NCT03179904 | Active, not recruiting | Phase 2 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | August 3, 2017 | July 30, 2024 |
| NCT03900884 | Active, not recruiting | Phase 1 | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer | September 25, 2019 | December 2025 |
| NCT05206448 | Active, not recruiting | Phase 4 | Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation | October 26, 2020 | December 2024 |
| NCT03900637 | Active, not recruiting | Phase 2 | PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate | November 8, 2019 | December 31, 2028 |
| NCT02246621 | Active, not recruiting | Phase 3 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer | November 6, 2014 | December 16, 2024 |
| NCT01791478 | Active, not recruiting | Phase 1 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | April 2013 | May 31, 2024 |
| NCT01797523 | Active, not recruiting | Phase 2 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | October 7, 2013 | October 31, 2025 |
| NCT05569811 | Active, not recruiting | Phase 2 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial | November 25, 2022 | July 31, 2030 |
| NCT05909397 | Active, not recruiting | Phase 3 | A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | August 9, 2023 | July 26, 2030 |
| NCT02228681 | Active, not recruiting | Phase 2 | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | May 21, 2015 | |
| NCT03822468 | Active, not recruiting | Phase 2 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | June 11, 2019 | July 1, 2024 |
| NCT01872260 | Active, not recruiting | Phase 1/Phase 2 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | October 22, 2013 | December 31, 2024 |
| NCT02221999 | Active, not recruiting | Phase 2/Phase 3 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | September 2013 | January 2029 |
| NCT02188745 | Active, not recruiting | Phase 2 | ER Reactivation Therapy for Breast Cancer | March 11, 2016 | October 2024 |
| NCT00999804 | Active, not recruiting | Phase 2 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | October 2011 | January 2024 |
| NCT03161353 | Active, not recruiting | Phase 2 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | June 26, 2017 | November 1, 2026 |
| NCT04551495 | Active, not recruiting | Phase 2 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) | January 14, 2021 | October 2024 |
| NCT00601900 | Active, not recruiting | Phase 3 | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | May 15, 2008 | July 10, 2024 |
| NCT01064635 | Active, not recruiting | Phase 3 | Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4) | August 2005 | August 2026 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT01068249 | Active, not recruiting | Phase 2 | Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | April 30, 2010 | April 30, 2028 |
| NCT02101788 | Active, not recruiting | Phase 2/Phase 3 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | February 27, 2014 | October 11, 2024 |
| NCT04546009 | Active, not recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | October 9, 2020 | March 18, 2027 |
| NCT00721409 | Completed | Phase 2 | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | September 15, 2008 | December 20, 2017 |
| NCT00728949 | Completed | Phase 2 | A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | August 2008 | February 2015 |
| NCT00754845 | Completed | Phase 3 | Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy | November 23, 2004 | April 19, 2017 |
| NCT00823004 | Completed | Phase 1/Phase 2 | Antagonist/Letrozole in Poor Responders | June 2008 | October 2009 |
| NCT00856050 | Completed | Phase 2 | Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | February 2009 | March 2014 |
| NCT00893061 | Completed | Phase 3 | Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer | March 16, 2009 | November 26, 2014 |
| NCT00903162 | Completed | Phase 2 | Extended Endocrine Therapy for Premenopausal Women With Breast Cancer | May 2009 | September 2014 |
| NCT00949598 | Completed | Phase 3 | Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer | December 2008 | October 2010 |
| NCT00956267 | Completed | N/A | Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome. | August 2006 | March 2009 |
| NCT00960960 | Completed | Phase 1 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | August 2009 | December 2015 |
| NCT00963729 | Completed | Phase 3 | Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery | September 2008 | March 2011 |
| NCT00997373 | Completed | N/A | Letrozole as a Treatment of Endometrial Cancer | October 2009 | September 2013 |
| NCT01035099 | Completed | Phase 4 | RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF | November 2009 | September 30, 2022 |
| NCT01046578 | Completed | Phase 4 | Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women | January 2010 | February 2012 |
| NCT01068704 | Completed | Phase 2 | Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer | June 2010 | December 2010 |
| NCT01077453 | Completed | Phase 1 | Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer | March 2010 | |
| NCT01105312 | Completed | Phase 1/Phase 2 | Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer | September 2010 | September 3, 2013 |
| NCT01129622 | Completed | Phase 2 | Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) | October 2008 | September 2010 |
| NCT01153672 | Completed | N/A | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | November 2010 | August 11, 2016 |
| NCT01194440 | Completed | Phase 2 | Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms | February 2011 | January 2014 |
| NCT01231659 | Completed | Phase 2 | Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | August 9, 2011 | April 30, 2017 |
| NCT01248494 | Completed | Phase 1 | PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer | November 2010 | May 2016 |
| NCT01296555 | Completed | Phase 1 | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | March 16, 2011 | June 25, 2021 |
| NCT01315912 | Completed | Phase 4 | Dosage Optimization for Letrozole Treatment | January 2008 | December 2010 |
| NCT01353209 | Completed | Phase 2 | Letrozole for Lymphangioleiomyomatosis | May 2011 | September 2014 |
| NCT01367626 | Completed | Phase 1 | Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions | March 2008 | April 2008 |
| NCT01367652 | Completed | Phase 1 | Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions | March 2008 | April 2008 |
| NCT01372982 | Completed | Phase 1 | Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions | April 2008 | June 2008 |
| NCT01375452 | Completed | Phase 1 | Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions | March 2008 | May 2008 |
| NCT01439711 | Completed | Phase 2 | Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ | February 2012 | January 2018 |
| NCT01457703 | Completed | N/A | Reproductive Hormonal Alterations in Obesity | June 2010 | July 2013 |
| NCT01553903 | Completed | Phase 4 | Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not | December 2011 | May 2013 |
| NCT01577017 | Completed | Phase 3 | The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) | May 2008 | March 2012 |
| NCT01655225 | Completed | Phase 1 | A Study of LY3023414 in Participants With Advanced Cancer | July 31, 2012 | February 2, 2022 |
| NCT01669343 | Completed | N/A | Aromatase Inhibitor Host Factors Study | October 2012 | December 2016 |
| NCT01679574 | Completed | N/A | Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome | January 2009 | January 2012 |
| NCT01684215 | Completed | Phase 2 | A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer | October 19, 2012 | October 25, 2018 |
| NCT01686828 | Completed | Phase 1/Phase 2 | T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin | June 2013 | December 2017 |
| NCT01698918 | Completed | Phase 2 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | March 7, 2013 | January 13, 2021 |
| NCT01720602 | Completed | N/A | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | November 2012 | January 2020 |
| NCT01740427 | Completed | Phase 3 | A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | February 22, 2013 | November 9, 2023 |
| NCT01797718 | Completed | Phase 2/Phase 3 | Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment | October 2013 | February 5, 2018 |
| NCT01814397 | Completed | Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients | July 2009 | February 2013 | |
| NCT01870505 | Completed | Phase 1 | BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer | May 2013 | February 28, 2022 |
| NCT01958021 | Completed | Phase 3 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) | December 17, 2013 | March 16, 2023 |
| NCT01989780 | Completed | Phase 2 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | January 2014 | June 2019 |
| NCT01999569 | Completed | Phase 4 | The Role of Estrogen in Luteinizing Hormone Surge and Ovulation | April 2007 | May 2008 |
| NCT02005887 | Completed | Phase 2 | TRial on the Endocrine Activity of Neoadjuvant Degarelix | February 2014 | August 25, 2017 |
| NCT02010021 | Completed | N/A | Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. | January 2014 | December 8, 2017 |
| NCT02093351 | Completed | Phase 1 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | September 1, 2014 | April 29, 2019 |
| NCT02097680 | Completed | Phase 4 | Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men | December 2013 | June 2015 |
| NCT00001521 | Completed | Phase 4 | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | June 8, 1995 | April 1, 2024 |
| NCT00003140 | Completed | Phase 3 | Letrozole After Tamoxifen in Treating Women With Breast Cancer | August 24, 1998 | October 2003 |
| NCT00004205 | Completed | Phase 3 | Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer | March 1998 | June 30, 2016 |
| NCT00004251 | Completed | Phase 2 | Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer | January 19, 2000 | January 18, 2011 |
| NCT00006174 | Completed | Phase 1 | Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome | August 3, 2000 | May 18, 2009 |
| NCT00014638 | Completed | Phase 4 | Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | January 2001 | March 2002 |
| NCT00044291 | Completed | Phase 3 | Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | June 2002 | January 2006 |
| NCT00050011 | Completed | Phase 3 | Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy | September 2002 | January 2009 |
| NCT00062751 | Completed | Phase 2 | Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms | December 2002 | October 2009 |
| NCT00073528 | Completed | Phase 3 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | December 9, 2003 | March 22, 2018 |
| NCT00084396 | Completed | Phase 2 | Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer | October 2003 | September 2016 |
| NCT00090857 | Completed | Phase 2 | Letrozole in Preventing Breast Cancer in Postmenopausal Women | February 2002 | March 2013 |
| NCT00107263 | Completed | Phase 3 | Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer | January 2005 | August 2012 |
| NCT00114270 | Completed | N/A | Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density | May 2004 | June 2007 |
| NCT00134680 | Completed | Phase 2 | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | January 2000 | July 2005 |
| NCT00171314 | Completed | Phase 3 | The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer | March 2004 | |
| NCT00171340 | Completed | Phase 3 | Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. | May 2003 | February 2010 |
| NCT00171704 | Completed | Phase 3 | A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | April 2005 | March 2011 |
| NCT00171808 | Completed | Phase 2 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer | April 2005 | |
| NCT00194779 | Completed | Phase 2 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | October 2003 | June 2011 |
| NCT00199134 | Completed | Phase 2 | FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole | November 2004 | December 2014 |
| NCT00237133 | Completed | Phase 4 | Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women | March 2003 | January 21, 2009 |
| NCT00237198 | Completed | Phase 2 | Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment | March 2004 | |
| NCT00237211 | Completed | Phase 2 | Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | June 2001 | October 2006 |
| NCT00237224 | Completed | Phase 4 | Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole | February 2003 | |
| NCT00238316 | Completed | Phase 2 | Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density | December 5, 2000 | February 10, 2009 |
| NCT00240942 | Completed | Phase 2 | Letrozole in the Treatment of Severe and Recurrent Endometriosis | October 2002 | June 2006 |
| NCT00247663 | Completed | Phase 2 | Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | December 1999 | |
| NCT00248170 | Completed | Phase 3 | Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | December 2005 | September 2014 |
| NCT00265759 | Completed | Phase 3 | Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | January 2006 | November 27, 2019 |
| NCT00290745 | Completed | Phase 1/Phase 2 | Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ | February 19, 2002 | June 30, 2011 |
| NCT00291135 | Completed | Phase 2 | Protocol for Women at Increased Risk of Developing Breast Cancer | January 2003 | October 2008 |
| NCT00305825 | Completed | Phase 2 | Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | August 2004 | May 24, 2016 |
| NCT00329940 | Completed | Phase 3 | Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | November 2005 | |
| NCT00330317 | Completed | Phase 3 | Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer | February 2006 | November 16, 2010 |
| NCT00332709 | Completed | Phase 3 | Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | January 2006 | August 2010 |
| NCT00332852 | Completed | Phase 3 | Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | March 2006 | |
| NCT00333047 | Completed | Phase 2/Phase 3 | Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy | July 2002 | |
| NCT00333086 | Completed | Phase 2 | A Study of Letrozole in the Treatment of Endometrial Cancer | January 2000 | |
| NCT00338728 | Completed | Phase 2 | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | October 3, 2003 | November 27, 2018 |
| NCT00416715 | Completed | Phase 2 | Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer | October 2006 | May 2010 |
| NCT00422903 | Completed | Phase 2 | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer | April 2007 | April 2011 |
| NCT00433589 | Completed | Phase 3 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | February 2007 | March 2020 |
| NCT00478504 | Completed | Phase 4 | Letrozole Versus Clomifene Citrate for Ovulation Induction | May 2007 | September 2014 |
| NCT00535418 | Completed | Phase 2/Phase 3 | Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers | June 2000 | |
| NCT00545077 | Completed | Phase 3 | Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women | November 6, 2007 | July 24, 2014 |
| NCT00553410 | Completed | Phase 3 | Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer | August 2007 | May 15, 2019 |
| NCT00565240 | Completed | N/A | Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women | November 2007 | September 2009 |
| NCT00579826 | Completed | Phase 2 | Study of Breast Cancer Prevention by Letrozole in High Risk Women | October 2006 | August 2018 |
| NCT00610077 | Completed | Phase 3 | Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility | December 2004 | July 2006 |
| NCT00634634 | Completed | Phase 1/Phase 2 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | August 11, 2008 | April 28, 2023 |
| NCT00673335 | Completed | Phase 3 | Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation | May 2008 | December 2023 |
| NCT00681928 | Completed | Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy | October 2007 | January 2011 | |
| NCT00688909 | Completed | Phase 4 | Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer | March 2008 | June 2009 |
| NCT00696072 | Completed | Phase 2 | Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic | August 2008 | June 2014 |
| NCT00708214 | Completed | Phase 2 | BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer | January 2007 | |
| NCT00719186 | Completed | Phase 3 | Pregnancy in Polycystic Ovary Syndrome II | February 2009 | May 2013 |
| NCT00719966 | Completed | Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer | September 18, 2008 | January 24, 2020 | |
| NCT02137538 | Completed | Phase 4 | Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole | November 18, 2009 | June 5, 2018 |
| NCT02152943 | Completed | Phase 1 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | July 17, 2014 | December 14, 2020 |
| NCT02154776 | Completed | Phase 1 | Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. | June 27, 2014 | October 26, 2016 |
| NCT02158689 | Completed | N/A | Comparison of Treatment Modalities in Poor Responders Undergoing IVF | June 2014 | August 2015 |
| NCT02273973 | Completed | Phase 2 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | November 12, 2014 | March 13, 2017 |
| NCT02278120 | Completed | Phase 3 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | November 20, 2014 | April 20, 2023 |
| NCT02283658 | Completed | Phase 2 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | November 14, 2014 | June 21, 2018 |
| NCT02291913 | Completed | Phase 2 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | December 18, 2014 | January 31, 2019 |
| NCT02294773 | Completed | N/A | Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit | October 2013 | September 2015 |
| NCT02296801 | Completed | Phase 2 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | January 2015 | March 2019 |
| NCT02304107 | Completed | Phase 3 | Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. | May 2013 | January 2015 |
| NCT02333370 | Completed | Phase 1 | A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | February 4, 2015 | September 29, 2022 |
| NCT02344550 | Completed | Phase 2 | Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer | January 2014 | October 2018 |
| NCT02389088 | Completed | N/A | Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH. | April 2006 | January 2013 |
| NCT02400567 | Completed | Phase 2 | Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women | January 2015 | September 2020 |
| NCT02401425 | Completed | Phase 2/Phase 3 | Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion | March 2015 | September 2015 |
| NCT02405156 | Completed | Phase 2/Phase 3 | Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion | March 2015 | December 2016 |
| NCT02455154 | Completed | Phase 2 | Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy | May 2015 | September 2019 |
| NCT02457312 | Completed | Phase 2 | The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues | March 2013 | December 2013 |
| NCT02470741 | Completed | Phase 4 | Pilot of Letrozole for Uterine Myomas | July 2015 | December 2017 |
| NCT02491320 | Completed | Phase 3 | The Clinical Trial of Acupuncture Pre-treatment on PCOS | August 2015 | October 2019 |
| NCT02491983 | Completed | Phase 2 | Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer | August 2015 | January 2020 |
| NCT02520063 | Completed | Phase 1/Phase 2 | Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer | February 1, 2016 | December 2022 |
| NCT02538484 | Completed | Early Phase 1 | Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects | April 2016 | March 26, 2020 |
| NCT02549430 | Completed | Phase 2 | To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | October 2012 | February 9, 2017 |
| NCT02600923 | Completed | Phase 3 | Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate | April 15, 2016 | May 28, 2019 |
| NCT02619162 | Completed | Phase 1 | Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics | July 2015 | June 2018 |
| NCT02648477 | Completed | Phase 2 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | March 28, 2016 | December 30, 2023 |
| NCT02657928 | Completed | Phase 2 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | July 8, 2016 | October 7, 2020 |
| NCT02670304 | Completed | Phase 4 | Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS | January 2012 | August 2013 |
| NCT02679755 | Completed | Phase 4 | Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer | March 9, 2016 | July 25, 2019 |
| NCT02684032 | Completed | Phase 1 | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | June 14, 2016 | January 19, 2022 |
| NCT02701348 | Completed | N/A | Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers | May 2016 | December 24, 2020 |
| NCT02703649 | Completed | Phase 4 | Administration of Single High Dose Letrozole for Ovulation Induction | March 2016 | July 31, 2020 |
| NCT02730429 | Completed | Phase 2 | Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer | February 15, 2017 | December 15, 2021 |
| NCT02739516 | Completed | Phase 3 | Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility | June 2014 | August 2015 |
| NCT02742051 | Completed | Phase 2 | A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | June 2016 | March 14, 2020 |
| NCT02802748 | Completed | Early Phase 1 | Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) | July 2016 | January 2018 |
| NCT02802865 | Completed | Phase 4 | Combined Letrozole and Clomid in Women With Infertility and PCOS | August 2016 | February 2019 |
| NCT02806050 | Completed | Phase 2 | Palbociclib and FES PET | September 16, 2016 | September 28, 2022 |
| NCT02865681 | Completed | N/A | Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization | July 1, 2016 | June 7, 2017 |
| NCT02894398 | Completed | Phase 2 | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | September 6, 2016 | February 15, 2023 |
| NCT02900105 | Completed | Phase 3 | Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia. | February 2015 | March 2017 |
| NCT02912988 | Completed | Phase 3 | Letrozole in Stimulated IVF Cycles | March 1, 2018 | April 30, 2023 |
| NCT02939898 | Completed | Phase 2/Phase 3 | Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | August 2016 | January 2018 |
| NCT02941926 | Completed | Phase 3 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC | November 30, 2016 | November 9, 2022 |
| NCT02946684 | Completed | Phase 2/Phase 3 | Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | February 1, 2017 | October 30, 2018 |
| NCT03007979 | Completed | Phase 2 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | June 15, 2017 | March 31, 2023 |
| NCT03096847 | Completed | Phase 3 | Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer | October 24, 2016 | February 6, 2020 |
| NCT03181919 | Completed | N/A | Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS | January 1, 2016 | March 1, 2017 |
| NCT03241472 | Completed | Phase 3 | Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole | February 2016 | June 2017 |
| NCT03272477 | Completed | Phase 2 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | October 5, 2017 | March 4, 2024 |
| NCT03285802 | Completed | Phase 2/Phase 3 | Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation | September 7, 2017 | February 12, 2019 |
| NCT03306472 | Completed | Phase 2 | A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer | July 20, 2017 | October 31, 2023 |
| NCT03378297 | Completed | Early Phase 1 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC | May 4, 2018 | January 5, 2023 |
| NCT03439046 | Completed | Phase 3 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant | February 2, 2018 | December 11, 2023 |
| NCT03455426 | Completed | N/A | Intrauterine Insemination With Letrozole Versus in Natural Cycle | March 15, 2018 | December 31, 2019 |
| NCT03555877 | Completed | Phase 2 | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | March 15, 2018 | July 21, 2022 |
| NCT03628066 | Completed | Phase 2 | Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | October 22, 2018 | January 30, 2021 |
| NCT03644186 | Completed | Phase 2 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | April 16, 2019 | April 14, 2023 |
| NCT03691493 | Completed | Phase 2 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | February 8, 2019 | October 13, 2022 |
| NCT03774472 | Completed | Phase 1/Phase 2 | Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | August 20, 2018 | April 17, 2024 |
| NCT04129216 | Completed | Phase 2 | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | February 20, 2019 | November 10, 2022 |
| NCT04130152 | Completed | Early Phase 1 | Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy | November 21, 2019 | February 24, 2022 |
| NCT04177693 | Completed | Phase 1 | Pharmacokinetics and Hepatic Safety of EGCG | November 24, 2020 | January 31, 2022 |
| NCT04256941 | Completed | Phase 2 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | May 31, 2019 | September 22, 2023 |
| NCT04258163 | Completed | Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | January 1, 2019 | July 1, 2019 | |
| NCT04294225 | Completed | Phase 2 | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | April 28, 2020 | December 12, 2022 |
| NCT05075863 | Completed | N/A | Efficacy of Letrozole Versus Clomiphene Citrate on Ovulation Induction in Patients With Polycystic Ovarian Syndrome | January 1, 2021 | June 30, 2021 |
| NCT06426979 | Completed | N/A | Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy | January 1, 2023 | January 1, 2024 |
| NCT02142868 | No longer available | Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate | |||
| NCT06380751 | Not yet recruiting | Phase 3 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | April 18, 2024 | July 18, 2030 |
| NCT06366347 | Not yet recruiting | Phase 2 | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | September 2024 | March 1, 2029 |
| NCT06452719 | Not yet recruiting | Phase 2 | Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study | July 15, 2024 | July 15, 2025 |
| NCT06348134 | Not yet recruiting | Phase 2 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | July 1, 2024 | July 1, 2036 |
| NCT06346457 | Not yet recruiting | Breast Cancer & Antiestrogenic Therapy & Brain | April 1, 2024 | April 1, 2026 | |
| NCT06223698 | Not yet recruiting | Phase 3 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer | May 2, 2024 | May 2, 2035 |
| NCT02686151 | Not yet recruiting | Phase 3 | The Letrozole Administration During Luteal Phase | December 2023 | December 2024 |
| NCT06179303 | Not yet recruiting | Phase 2 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | July 6, 2024 | June 1, 2026 |
| NCT04942899 | Not yet recruiting | Phase 2 | Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer | August 30, 2023 | May 31, 2025 |
| NCT04321551 | Not yet recruiting | Phase 4 | Hormone Secretion in Transgender Males | July 1, 2023 | December 31, 2028 |
| NCT06405178 | Not yet recruiting | Phase 3 | Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome | September 30, 2024 | December 30, 2024 |
| NCT06465368 | Not yet recruiting | Phase 2 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | July 2, 2024 | October 15, 2025 |
| NCT05766410 | Recruiting | Phase 2 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC | September 16, 2022 | September 30, 2026 |
| NCT05774951 | Recruiting | Phase 3 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | March 31, 2023 | May 29, 2036 |
| NCT05809024 | Recruiting | Phase 4 | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy | March 1, 2023 | March 25, 2026 |
| NCT05867251 | Recruiting | Phase 1/Phase 2 | Study of AVZO-021 in Patients With Advanced Solid Tumors | August 30, 2023 | January 31, 2030 |
| NCT05872204 | Recruiting | Phase 2 | Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer | November 30, 2023 | October 2026 |
| NCT05891093 | Recruiting | Phase 3 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | June 1, 2023 | May 31, 2031 |
| NCT05900206 | Recruiting | Phase 2 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | October 26, 2023 | April 30, 2032 |
| NCT03011684 | Recruiting | Phase 3 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | July 21, 2016 | January 31, 2025 |
| NCT05940233 | Recruiting | N/A | Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone | June 30, 2023 | May 30, 2025 |
| NCT03135301 | Recruiting | Phase 3 | Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome | June 20, 2017 | March 2024 |
| NCT05952557 | Recruiting | Phase 3 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | October 5, 2023 | May 6, 2037 |
| NCT06001762 | Recruiting | Phase 2 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | October 5, 2023 | January 1, 2027 |
| NCT06006091 | Recruiting | N/A | The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET) | August 1, 2023 | August 1, 2027 |
| NCT06016738 | Recruiting | Phase 3 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | November 16, 2023 | September 30, 2027 |
| NCT06072781 | Recruiting | Phase 3 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | March 18, 2024 | February 9, 2031 |
| NCT06075953 | Recruiting | Phase 2 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | February 14, 2024 | November 2033 |
| NCT06120283 | Recruiting | Phase 1 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | December 1, 2023 | May 2026 |
| NCT06139107 | Recruiting | Phase 1 | RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | June 21, 2024 | September 30, 2032 |
| NCT06253195 | Recruiting | Phase 1 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | April 1, 2024 | October 26, 2026 |
| NCT03675893 | Recruiting | Phase 2 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | December 24, 2018 | August 1, 2029 |
| NCT03879577 | Recruiting | Phase 2 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | November 25, 2019 | April 10, 2024 |
| NCT03906669 | Recruiting | Phase 2 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. | March 20, 2018 | April 2024 |
| NCT04095364 | Recruiting | Phase 3 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | September 20, 2019 | February 1, 2028 |
| NCT04169451 | Recruiting | N/A | IUI With Letrozole Versus in Natural Cycle | September 29, 2022 | June 2026 |
| NCT06394804 | Recruiting | Phase 2 | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | April 29, 2024 | April 2027 |
| NCT06418347 | Recruiting | Phase 3 | Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females | April 1, 2024 | April 1, 2025 |
| NCT04282031 | Recruiting | Phase 1/Phase 2 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | June 15, 2020 | March 15, 2024 |
| NCT04289805 | Recruiting | Phase 4 | Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) | February 25, 2019 | January 30, 2029 |
| NCT04469764 | Recruiting | Phase 2 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | October 16, 2020 | July 1, 2026 |
| NCT02095184 | Recruiting | N/A | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | May 25, 2015 | March 20, 2025 |
| NCT04486352 | Recruiting | Phase 1/Phase 2 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | October 20, 2021 | October 2026 |
| NCT04557449 | Recruiting | Phase 1/Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | September 23, 2020 | May 4, 2028 |
| NCT04606446 | Recruiting | Phase 1 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors | November 16, 2020 | November 8, 2026 |
| NCT04614194 | Recruiting | Phase 2 | Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | April 15, 2021 | April 15, 2028 |
| NCT04964934 | Recruiting | Phase 3 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | June 30, 2021 | November 26, 2027 |
| NCT04985266 | Recruiting | Phase 2 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | March 30, 2022 | September 1, 2030 |
| NCT05161195 | Recruiting | Phase 4 | Roll-over Study to Allow Continued Access to Ribociclib | July 7, 2022 | March 26, 2030 |
| NCT05183828 | Recruiting | Phase 4 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | January 23, 2022 | December 31, 2024 |
| NCT05226871 | Recruiting | Phase 2 | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | July 7, 2022 | April 19, 2026 |
| NCT05304273 | Recruiting | Phase 3 | Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages | May 5, 2022 | May 2024 |
| NCT05341817 | Recruiting | Phase 4 | The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy | November 22, 2022 | November 2024 |
| NCT05447910 | Recruiting | Phase 2 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer | July 21, 2022 | June 15, 2025 |
| NCT05464810 | Recruiting | Early Phase 1 | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | September 2, 2022 | April 15, 2025 |
| NCT05467891 | Recruiting | Phase 2 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | September 13, 2022 | December 2027 |
| NCT05487092 | Recruiting | N/A | Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy | December 1, 2022 | June 30, 2027 |
| NCT05514054 | Recruiting | Phase 3 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | October 4, 2022 | March 15, 2032 |
| NCT05582499 | Recruiting | Phase 1/Phase 2 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | November 1, 2022 | September 2025 |
| NCT05638594 | Recruiting | Phase 2 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | December 20, 2022 | December 10, 2027 |
| NCT02778685 | Recruiting | Phase 2 | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | September 30, 2016 | December 30, 2024 |
| NCT05649956 | Recruiting | Phase 2 | Letrozole in Uterine Leiomyosarcoma | March 1, 2024 | June 30, 2029 |
| NCT05827081 | Suspended | Phase 3 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | February 28, 2024 | September 20, 2030 |
| NCT04577001 | Terminated | Phase 2 | Letrozole in Patients With Hepatopulmonary Syndrome | February 18, 2021 | March 26, 2021 |
| NCT01208441 | Terminated | Phase 1 | RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer | November 2010 | |
| NCT00414076 | Terminated | Phase 2 | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | December 19, 2006 | July 13, 2017 |
| NCT00171847 | Terminated | Phase 4 | Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer | March 2003 | |
| NCT00499681 | Terminated | Phase 2 | PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE | July 2007 | December 2010 |
| NCT00573755 | Terminated | Phase 2 | Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer | December 2007 | April 2013 |
| NCT01615211 | Terminated | Phase 2 | Randomized Study of Letrozole and Trilostane for Medical Abortion | May 2012 | October 2013 |
| NCT00549822 | Terminated | Phase 2 | Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | October 2007 | September 2013 |
| NCT01205685 | Terminated | Phase 2 | Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer | May 2010 | July 2011 |
| NCT02585388 | Terminated | Phase 2 | Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. | October 23, 2015 | May 15, 2017 |
| NCT00498901 | Terminated | Phase 2 | Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer | February 2007 | November 2008 |
| NCT01499160 | Terminated | Phase 2 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | May 2012 | December 2016 |
| NCT01430585 | Terminated | Phase 2 | Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer | March 2012 | December 2012 |
| NCT03050398 | Terminated | Phase 3 | A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib | June 7, 2017 | March 8, 2019 |
| NCT00611715 | Terminated | Phase 2 | Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer. | November 2003 | December 2008 |
| NCT00267553 | Terminated | Phase 3 | Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer | November 2005 | June 2006 |
| NCT03128619 | Terminated | Phase 1 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | August 2, 2017 | March 31, 2022 |
| NCT00101062 | Terminated | Phase 2 | Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | January 2004 | December 2005 |
| NCT00651976 | Terminated | Early Phase 1 | Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery | March 2008 | September 2018 |
| NCT00770354 | Terminated | Phase 2 | Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer | September 2008 | August 2011 |
| NCT01368263 | Terminated | Phase 2 | Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | September 2011 | May 2013 |
| NCT00880009 | Terminated | Phase 2 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | July 30, 2009 | May 31, 2010 |
| NCT03220178 | Terminated | Phase 4 | Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | July 24, 2017 | December 7, 2021 |
| NCT00796107 | Terminated | Phase 2 | A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer | January 28, 2009 | March 3, 2010 |
| NCT04478266 | Terminated | Phase 3 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer | October 14, 2020 | May 26, 2023 |
| NCT02907918 | Terminated | Phase 2 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer | June 30, 2017 | September 23, 2020 |
| NCT04191382 | Terminated | Phase 2 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer | February 4, 2020 | May 28, 2021 |
| NCT00263198 | Terminated | Phase 2 | PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer | March 2006 | November 2006 |
| NCT02115048 | Terminated | Phase 2 | Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone | July 2014 | November 2018 |
| NCT02730091 | Terminated | Phase 3 | A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease | February 24, 2016 | March 23, 2020 |
| NCT01225172 | Terminated | Phase 2 | Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors | December 31, 2010 | November 30, 2014 |
| NCT00375752 | Terminated | Phase 4 | Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer | June 1, 2006 | December 16, 2010 |
| NCT00505661 | Terminated | Phase 2 | Letrozole in Patients With Ovarian Tumors | September 2003 | May 2010 |
| NCT00097344 | Terminated | Phase 3 | The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | December 2004 | August 2006 |
| NCT01919229 | Terminated | Phase 2 | A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) | October 2013 | September 2014 |
| NCT00516542 | Terminated | Phase 1 | Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer | June 2007 | December 2010 |
| NCT00241046 | Terminated | Phase 4 | Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment | April 2002 | |
| NCT04102618 | Terminated | Early Phase 1 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | March 29, 2019 | April 20, 2022 |
| NCT02269670 | Terminated | Phase 2 | Phase II Study of Everolimus Beyond Progression | November 25, 2014 | January 25, 2021 |
| NCT00461773 | Terminated | Phase 2 | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | March 2007 | May 2010 |
| NCT00902954 | Unknown status | Phase 3 | Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer | March 2008 | June 2011 |
| NCT04047758 | Unknown status | Phase 3 | Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer | September 1, 2019 | September 30, 2022 |
| NCT04049227 | Unknown status | Early Phase 1 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | August 12, 2019 | July 1, 2023 |
| NCT02551367 | Unknown status | Phase 2 | Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS ) | October 2015 | July 2016 |
| NCT04095390 | Unknown status | Phase 2 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | September 30, 2019 | August 30, 2022 |
| NCT03009838 | Unknown status | Phase 3 | Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome | January 2, 2017 | August 2023 |
| NCT02630485 | Unknown status | N/A | Graceful Lifestyle Changes Study for PCOS and Infertility | December 2015 | August 2018 |
| NCT04308343 | Unknown status | N/A | The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy | March 30, 2020 | September 1, 2022 |
| NCT02958852 | Unknown status | Phase 2 | A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer | November 2016 | April 2024 |
| NCT04361175 | Unknown status | Early Phase 1 | Cost Effectiveness Analysis for Induction of Ovulation in the Polycystic Ovary Syndrome by Letrozole Versus Clomiphene Citrate | March 2021 | December 2021 |
| NCT04364581 | Unknown status | Phase 4 | Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions | May 1, 2020 | May 1, 2021 |
| NCT02647424 | Unknown status | N/A | A Comparison of Letrozole and Clomifene Citrate | December 2015 | December 2017 |
| NCT01431352 | Unknown status | N/A | Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) | September 2009 | August 2014 |
| NCT00351416 | Unknown status | Phase 1/Phase 2 | Letrozole Treatment in Normal and GnRH Deficient Women | January 21, 2004 | |
| NCT01475318 | Unknown status | N/A | Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy | October 2011 | June 2012 |
| NCT02214004 | Unknown status | Phase 2 | Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women | March 2015 | June 2019 |
| NCT01908556 | Unknown status | Phase 4 | Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) | February 2009 | |
| NCT01814449 | Unknown status | Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer | March 2012 | May 2014 | |
| NCT01758146 | Unknown status | Phase 3 | Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors | January 2012 | June 2020 |
| NCT04590482 | Unknown status | Phase 4 | Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion | November 15, 2020 | May 8, 2021 |
| NCT00280930 | Unknown status | Phase 2 | Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer | October 2005 | |
| NCT02765373 | Unknown status | Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients | January 2015 | ||
| NCT04666805 | Unknown status | Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast | July 1, 2020 | January 15, 2021 | |
| NCT02305693 | Unknown status | Phase 3 | Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) | November 2014 | |
| NCT02313051 | Unknown status | Phase 2 | Everolimus trIal for Advanced prememopausaL Breast Cancer Patients | December 2014 | December 2017 |
| NCT04852081 | Unknown status | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | January 1, 2021 | December 1, 2021 | |
| NCT04856371 | Unknown status | Phase 1 | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | April 2021 | December 2022 |
| NCT02775877 | Unknown status | N/A | Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer | May 2016 | January 2020 |
| NCT02450175 | Unknown status | N/A | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | June 2014 | June 2016 |
| NCT04987632 | Unknown status | Phase 1 | Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS | August 3, 2021 | December 31, 2022 |
| NCT03373708 | Unknown status | Phase 2/Phase 3 | Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | December 20, 2017 | December 20, 2019 |
| NCT02482740 | Unknown status | Phase 2 | A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix | May 2015 | June 2017 |
| NCT03400683 | Unknown status | N/A | Different Methods of Termination of Second Trimester Abortion | January 2018 | July 2018 |
| NCT05106712 | Unknown status | N/A | Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women | November 1, 2021 | November 1, 2023 |
| NCT03497702 | Unknown status | Phase 2 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | May 8, 2017 | January 2024 |
| NCT03540979 | Unknown status | N/A | Endometrial Preparation in Frozen Embryo Transfer Cycles | June 2018 | December 2019 |
| NCT01072318 | Unknown status | Phase 4 | Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene | January 2010 | January 2014 |
| NCT03625531 | Unknown status | Phase 3 | A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS | August 13, 2018 | January 31, 2024 |
| NCT02499146 | Unknown status | Phase 1 | Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer | September 11, 2015 | January 30, 2023 |
| NCT00688194 | Unknown status | Phase 3 | Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | May 2008 | |
| NCT00687648 | Unknown status | Phase 2 | Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | May 2008 | |
| NCT02689921 | Unknown status | Phase 2 | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer | April 2016 | December 2018 |
| NCT01116167 | Unknown status | N/A | Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine | October 2009 | December 2013 |
| NCT00541086 | Unknown status | Phase 3 | Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery | March 2007 | July 2020 |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT02619669 | Withdrawn | Phase 1 | Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | April 20, 2017 | June 14, 2019 |
| NCT00804960 | Withdrawn | Phase 4 | Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? | September 2008 | April 2010 |
| NCT04193930 | Withdrawn | N/A | Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles | January 1, 2021 | January 1, 2021 |
| NCT01013506 | Withdrawn | Phase 2 | Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer | August 2009 | December 2009 |
| NCT04872608 | Withdrawn | Phase 1 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | September 9, 2021 | April 25, 2023 |
| NCT03238703 | Withdrawn | Phase 4 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | September 1, 2018 | March 14, 2025 |
| NCT02377479 | Withdrawn | N/A | Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles | March 2015 | |
| NCT04630210 | Withdrawn | Early Phase 1 | Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity | February 2021 | January 31, 2025 |
| NCT03058939 | Withdrawn | Phase 2 | Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | November 2018 | June 2019 |
| NCT04002635 | Withdrawn | Phase 4 | Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS) | December 1, 2020 | April 1, 2022 |
| NCT00403182 | Withdrawn | Phase 3 | Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer | May 2006 | |
| NCT04316169 | Withdrawn | Phase 1 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | October 21, 2021 | January 2028 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |